InfuSystems INFU 深 沪
等待开盘 10-30 09:30:00 美东时间
14.45
+0.130
+0.91%
华盛通- 最 高14.64
- 今 开14.47
- 成交量 7.49万股
- 最 低 14.235
- 昨 收 14.32
- 总市值 2.88亿
- 52周最高 14.64
- 市盈率 静 46.00
- 换手率 0.38%
- 52周最低 7.29
- 委 比 14.94%
- 总股本 1991.72万
- 历史最高 23.26
- 量 比 0.61
- 振 幅 2.83%
- 历史最低 0.75
- 每 手 1
- 风险率 1.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InfuSystems Holdings Inc收跌0.93%，成交额129.66万美元
10月27日，InfuSystems Holdings Inc（INFU）收跌0.93%，报13.81美元，成交额129.66万美元，市值2.75亿美元。 行情...
10-27 06:30
InfuSystems Holdings Inc收跌3.74%，成交额177.02万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:34
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
B. Riley Securities Reiterates Buy on InfuSystems Holdings, Raises Price Target to $20
B. Riley Securities analyst Anderson Schock reiterates InfuSystems Holdings (AMEX:INFU) with a Buy and raises the price target from $12 to $20.
08-06 00:49
InfuSystems Holdings Reports Q2 2026 Results: Full Earnings Call Transcript
InfuSystems Holdings (AMEX:INFU) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/ap...
08-04 21:33
InfuSystems Holdings Q2 EPS $0.15 Beats $0.11 Estimate, Sales $36.933M Beat $36.353M Estimate
InfuSystems Holdings (AMEX:INFU) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.11 by 36.36 percent. This is a 25 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $36.933 million ...
08-04 18:32
InfuSystem Holdings Approves New $20M Stock Buyback Program, Replacing Expiring Repurchase Authorization
InfuSystem Holdings, Inc.
05-19 04:31
InfuSystem Elects Beverly Huss Board Chairman
https://www.sec.gov/ix?doc=/Archives/edgar/data/1337013/000162828026034839/infu-20260511.htm
05-14 21:07
InfuSystem Reiterated FY26 Pro-forma Net Revenue Growth Of 6%-8% YoY
Full Year 2026 GuidanceInfuSystem is reaffirming annual net revenue guidance for the full year 2026. After adjusting for the impact of the reduced revenue related to the GE Healthcare contract restructuring, pro-forma
05-07 18:37
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
